Declining sales and profits due to drug price revisions, lower licensing income and increased research and development expenses

A theme in which revisions to drug prices, the decline from the previous period in upfront payments and licensing income from KRP-M223 and other products, and increased research and development expenses combine to reduce net sales and profit at each level.